As an extension of our previous work on donepezil-based “bio-oxidizable” prodrug
approach, two new classes of N-benzylpyridinium donepezil analogues in tetralone B2 and …

With the aim of reducing side effects of acetylcholinesterase inhibitors (AChEIs) during
symptomatic treatment of Alzheimer's disease, we report herein a new class of donepezil …

Herein, we report a new class of dual binding site AChE inhibitor 4 designed to exert a
central cholinergic activation thanks to a redox-activation step of a prodrug precursor 3 …

Sixty-four new indanones and thiaindanones related to donepezil were synthesized and
evaluated in vitro as potential AChE inhibitors. Among them, 11 derivatives were found to …

Chloro-pyridonepezils are chloropyridine–donepezil hybrids designed by combining the N-
benzylpiperidine moiety present in donepezil with the 2-chloropyridine-3, 5-dicarbonitrile …

The synthesis, biological assessment and molecular modeling of new pyridonepezils1–8,
able to inhibit human acetylcholinesterase (hAChE) and human butyrylcholinesterase …

A new series of sixteen multifunctional N-benzyl-piperidine-aryl-acylhydrazones hybrid
derivatives was synthesized and evaluated for multi-target activities related to Alzheimer's …

The selective AChE inhibitor donepezil has been approved by the FDA as a first-line drug for
the treatment of mild to moderate AD. However, many peripheral side effects were observed …

A series of benzofuran-based N-benzylpyridinium derivatives 5a–o were designed and
synthesized as novel AChE inhibitors. The synthetic pathway of the compounds involved the …

Abstract A series of quinazolin-4 (3H)-one derivatives was designed through scaffold-
hopping strategy and synthesized as novel multifunctional anti-AD agents demonstrating …